Illumina Signs Agreement to Acquire NextBio, Leader in Analyzing and Aggregating Complex Genomic Data
Acquisition Will Strengthen Illumina's Informatics Portfolio, Enable Accelerated Adoption of Next-Generation Sequencing in Current and New Markets
SAN DIEGO--(BUSINESS WIRE)--October 28, 2013--
Illumina, Inc. (NASDAQ:ILMN) today announced it has signed a definitive agreement to acquire Santa Clara-based NextBio, a leader in clinical and genomic informatics. NextBio's powerful big-data platforms aggregate and analyze large quantities of phenotypic and genomic data for research and clinical applications. With the addition of NextBio's platform upon completion of the acquisition, Illumina will be able to offer customers enterprise level bioinformatics solutions that accelerate the discovery of new associations between the human genome and disease, and ultimately, enable the application of those discoveries within healthcare.
"This agreement with NextBio demonstrates Illumina's unwavering commitment to drive the adoption of sequencing in new markets and vastly improve the genomic information workflow," said Jay Flatley, President and CEO of Illumina. "NextBio enables the classification and aggregation of phenotypic and clinical data within a single environment and allows analysis of that data at unprecedented speed and scale. The combination of Illumina's BaseSpace cloud computing environment for next-generation sequencing with NextBio's platform for integrating patient data will allow us to deliver solutions that seamlessly integrate the entire workflow from sample to result."
NextBio's platform allows customers to quickly compare their experimental results against thousands of published and private data sets by means of a unique correlation engine, which pre-computes billions of significant connections between disparate data elements and helps discover new associations. NextBio Clinical, which in 2012 passed an independent HIPAA audit, is designed for seamless integration with existing clinical and research systems. Backed by highly scalable Software as a Service (SaaS) enterprise technology, it is capable of analyzing petabytes of data.
NextBio's database platforms are currently used by researchers and clinicians in more than 50 commercial and academic institutions. NextBio will be integrated into Illumina's newly formed Enterprise Informatics business under the leadership of Nick Naclerio, SVP of Corporate and Venture Development and General Manager of Enterprise Informatics. NextBio co-founder Ilya Kupershmidt and Chief Technology Officer Satnam Alag will continue to provide scientific and technical leadership as part of the new business unit.
Illumina is confirming its 2013 financial guidance provided on October 21, 2013. The transaction is expected to close by the end of October.
Illumina (www.illumina.com) is a leading developer, manufacturer, and marketer of life science tools and integrated systems for the analysis of genetic variation and function. We provide innovative sequencing and array-based solutions for genotyping, copy number variation analysis, methylation studies, gene expression profiling, and low-multiplex analysis of DNA, RNA, and protein. We also provide tools and services that are fueling advances in consumer genomics and diagnostics. Our technology and products accelerate genetic analysis research and its application, paving the way for molecular medicine and ultimately transforming healthcare.
This release may contain forward looking statements that involve risks and uncertainties. Important factors that could cause actual results to differ materially from those in any forward-looking statements are detailed in our filings with the Securities and Exchange Commission, including our most recent filings on Forms 10-K and 10-Q, or in information disclosed in public conference calls, the date and time of which are released beforehand. We do not intend to update any forward-looking statements after the date of this release.
CONTACT: Illumina, Inc.
SOURCE: Illumina, Inc. Copyright Business Wire 2013